Week in Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO

Deals and Financings • Tianjin CanSino Biologics will raise up to $160.5 million in a Hong Kong IPO to develop its 15 vaccine candidates, including an approved Ebola vaccine; • Abbisko Therapeutics of Shanghai completed a $42 million series B fundraising that it will use to start clinical trials of its oncology candidates; • GenoImmune, a BGI subsidiary, raised $18 million in an A funding round to support its neoantigen discovery of new immunotherapy candidates; • Sinopharm partnered with ImmunoBiology of Cambridge UK to co-develop ImmBio’s novel pneumonia vaccine and commercialize the vaccine in China; • Germany's Merck signed a non-binding MOU with China's GenScript to collaborate on offering CDMO plasmid and viral vector manufacturing services; Trials and Approvals • Guangzhou Xiangxue Life Sciences was approved to start China trials of its T-cell receptor Affinity Enhanced Specific T-cell therapy in patients with solid tumors; • I-Mab Biopharma dosed the first patient in a Phase II Taiwan trial of a CD38 antibody in patients with relapsed or refractory multiple myeloma; • I-Mab Biopharma also started a US Phase I trial of its humanized immunoglobulin G1 antibody targeting GM-CSF; • Innovent Biologics of Suzhou began a US Phase I trial of its anti-CD47 mAb candidate in patients with advanced malignant tumors; • Xynomic has been approved to start Phase III trials in China, Spain and Poland authorities of abexinostat in patients with renal cell carcinoma; Industry Insights • China's "Cambrian Explosion" of new drugs causes Franck Le Deu, Head of Greater China Healthcare practice at McKinsey, to distill five observations about the current state of drug development in China. Stock Symbols: (DE: MRK) (HK: 01801) Share this with colleagues: // //